
For research use only. We do not supply to patients.
For pharmaceutical-grade products or other inquiries, please contact our experts.
In Otsuka Long-Evans Tokushima Fatty rats, high-fructose diet increased body weight, epididymal fat, uric acid, cholesterol, triglycerides, hepatic enzymes, and NAFLD activity score. Allopurinol treatment reduced hepatic steatosis, epididymal fat, serum uric acid, HOMA-IR, and hepatic enzymes. It downregulated lipogenic genes, upregulated lipid oxidation genes, reduced pro-inflammatory cytokines, and decreased ER stress proteins. Allopurinol ameliorates fructose-induced hepatic steatosis through lipid metabolism, inflammation, and ER stress modulation, suggesting a role for uric acid in NAFLD.
Fig. 1 Effects of HFrD and allopurinol treatment on glucose tolerance test. (Cho IJ, et al., 2021)
References
In a phase 2b trial (861 patients with CKD and hyperuricemia), verinurad (a URAT1 inhibitor) combined with allopurinol did not reduce urinary albumin/creatinine ratio or eGFR decline compared to allopurinol alone or placebo at 34 or 60 weeks. Serum urate was dose‑dependently lowered. Adverse events were balanced. Verinurad does not provide renal benefit beyond urate lowering in this population.
Fig. 2 Correlation between change from baseline in UACR and serum urate for the different dose groups. (Heerspink HJL, et al., 2024)
References
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
All our products are chemicals for research purposes only. We do not supply for human or veterinary applications.
Privacy Policy | Cookie Policy Copyright © Protheragen. All Rights Reserved.
